382 related articles for article (PubMed ID: 20937839)
1. Cell fate determination factor Dachshund reprograms breast cancer stem cell function.
Wu K; Jiao X; Li Z; Katiyar S; Casimiro MC; Yang W; Zhang Q; Willmarth NE; Chepelev I; Crosariol M; Wei Z; Hu J; Zhao K; Pestell RG
J Biol Chem; 2011 Jan; 286(3):2132-42. PubMed ID: 20937839
[TBL] [Abstract][Full Text] [Related]
2. DACH1 suppresses breast cancer as a negative regulator of CD44.
Xu H; Yu S; Yuan X; Xiong J; Kuang D; Pestell RG; Wu K
Sci Rep; 2017 Jun; 7(1):4361. PubMed ID: 28659634
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
Bourguignon LY; Wong G; Earle C; Chen L
J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
[TBL] [Abstract][Full Text] [Related]
4. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L; Losi L; Leyvraz S; Benhattar J
PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
[TBL] [Abstract][Full Text] [Related]
5. DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth.
Wu K; Li A; Rao M; Liu M; Dailey V; Yang Y; Di Vizio D; Wang C; Lisanti MP; Sauter G; Russell RG; Cvekl A; Pestell RG
Mol Cell Biol; 2006 Oct; 26(19):7116-29. PubMed ID: 16980615
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells.
Saiki Y; Ishimaru S; Mimori K; Takatsuno Y; Nagahara M; Ishii H; Yamada K; Mori M
Ann Surg Oncol; 2009 Sep; 16(9):2638-44. PubMed ID: 19554373
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of NANOG and KLF4 for breast cancer.
Nagata T; Shimada Y; Sekine S; Hori R; Matsui K; Okumura T; Sawada S; Fukuoka J; Tsukada K
Breast Cancer; 2014 Jan; 21(1):96-101. PubMed ID: 22528804
[TBL] [Abstract][Full Text] [Related]
8. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
[TBL] [Abstract][Full Text] [Related]
9. [LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells].
Yan ZY; Sun XC
Zhonghua Bing Li Xue Za Zhi; 2018 Apr; 47(4):284-290. PubMed ID: 29690669
[No Abstract] [Full Text] [Related]
10. Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer.
Chen K; Wu K; Gormley M; Ertel A; Wang J; Zhang W; Zhou J; Disante G; Li Z; Rui H; Quong AA; McMahon SB; Deng H; Lisanti MP; Wang C; Pestell RG
Oncotarget; 2013 Jun; 4(6):923-35. PubMed ID: 23798621
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of clinical significance of stem-cell related factors in renal cell cancer.
Liu Y; Zhang C; Fan J; Xiao L; Yin B; Zhou L; Xia S
World J Surg Oncol; 2011 Oct; 9():121. PubMed ID: 21982273
[TBL] [Abstract][Full Text] [Related]
12. Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4, KLF4, Sox2, Nanog).
Lee S; Wottrich S; Bonavida B
Tumour Biol; 2017 Apr; 39(4):1010428317692253. PubMed ID: 28378634
[TBL] [Abstract][Full Text] [Related]
13. Forkhead Box Q1 Is a Novel Target of Breast Cancer Stem Cell Inhibition by Diallyl Trisulfide.
Kim SH; Kaschula CH; Priedigkeit N; Lee AV; Singh SV
J Biol Chem; 2016 Jun; 291(26):13495-508. PubMed ID: 27129776
[TBL] [Abstract][Full Text] [Related]
14. Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor.
Beltran AS; Rivenbark AG; Richardson BT; Yuan X; Quian H; Hunt JP; Zimmerman E; Graves LM; Blancafort P
Breast Cancer Res; 2011 Sep; 13(5):R94. PubMed ID: 21952072
[TBL] [Abstract][Full Text] [Related]
15. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer.
Cho Y; Lee HW; Kang HG; Kim HY; Kim SJ; Chun KH
Oncotarget; 2015 Apr; 6(11):8709-21. PubMed ID: 25909162
[TBL] [Abstract][Full Text] [Related]
16. Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors.
Nishi M; Sakai Y; Akutsu H; Nagashima Y; Quinn G; Masui S; Kimura H; Perrem K; Umezawa A; Yamamoto N; Lee SW; Ryo A
Oncogene; 2014 Jan; 33(5):643-52. PubMed ID: 23318426
[TBL] [Abstract][Full Text] [Related]
17. Reduced tumorigenicity and drug resistance through the downregulation of octamer-binding protein 4 and Nanog transcriptional factor expression in human breast stem cells.
Huang ZJ; You J; Luo WY; Chen BS; Feng QZ; Wu BL; Jiang L; Luo Q
Mol Med Rep; 2015 Mar; 11(3):1647-54. PubMed ID: 25405855
[TBL] [Abstract][Full Text] [Related]
18. ONSL and OSKM cocktails act synergistically in reprogramming human somatic cells into induced pluripotent stem cells.
Jung L; Tropel P; Moal Y; Teletin M; Jeandidier E; Gayon R; Himmelspach C; Bello F; André C; Tosch A; Mansouri A; Bruant-Rodier C; Bouillé P; Viville S
Mol Hum Reprod; 2014 Jun; 20(6):538-49. PubMed ID: 24501429
[TBL] [Abstract][Full Text] [Related]
19. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.
Corominas-Faja B; Cufí S; Oliveras-Ferraros C; Cuyàs E; López-Bonet E; Lupu R; Alarcón T; Vellon L; Iglesias JM; Leis O; Martín ÁG; Vazquez-Martin A; Menendez JA
Cell Cycle; 2013 Sep; 12(18):3109-24. PubMed ID: 23974095
[TBL] [Abstract][Full Text] [Related]
20. The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling.
Popov VM; Zhou J; Shirley LA; Quong J; Yeow WS; Wright JA; Wu K; Rui H; Vadlamudi RK; Jiang J; Kumar R; Wang C; Pestell RG
Cancer Res; 2009 Jul; 69(14):5752-60. PubMed ID: 19605405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
